It is with great excitement that we can today announce that RBR active™ and the RBR legflow™ have been awarded the Global Health and Pharma Excellence in DVT Prevention and Care Award 2021.
Medical technology, also known as ‘MedTech’, is intended to improve the quality of medical care we receive through earlier diagnosis, less invasive treatment options and reduction in hospital stays and rehabilitation times. MedTech includes and is not limited to: Medical Devices, Information Technology, Patient Portals, Implant Technology, Orthopaedics, Telemedicine and Mobile Health.
In 2019, the European Patent Office (EPO) received 14,000 patent applications in the field of medical technology representing a 0.9% growth in patent applications to the previous year. Furthermore, the European medical technology industry employs more than 730,000 people. These individuals work to ensure our healthcare professionals can give a higher quality of care.
This award goes a long way in confirming that the RBR legflow™ Deep Vein Thrombosis prevention device (approved by the Medicines and Healthcare products Regulatory Agency) has proved to be the healthcare and pharmaceutical industries go to proven medical device in the non-intrusive prevention, care and treatment of Thrombosis.
Paul Westerman, RBR active™ Director said; “To be recognised by the Global Health and Pharma Excellence judging committee and to be awarded the Excellence in DVT Prevention and Care Award 2021 for our innovative DVT prevention device is a wonderful accomplishment. Knowing that the global healthcare sector now has a proven, researched and trialled thrombosis device that saves lives, prevents Deep Vein Thrombosis and cares for patients post Thromboembolic event,is a superb testament for all the research, trials and hard work we’ve all undertaken since 2017.”
So, what does the future hold for the RBR legflow™? Paul says; “ideally we want to see the RBR legflow™ in all NHS and private healthcare facilities. Prevention not only saves lives, but also valuable budgets in the long run”.
During admission, patients are at a significantly greater risk of developing a deadly blood clot whilst being hospitalised. In fact, the number one cause of preventable death in hospital is VTE (VTE = DVT + PE). A recent clinical paper by the Imperial
Being sedentary for just a mere 90 minutes patients’ blood flow to the lower limbs has decreased by over 50%, it is this, that causes the potential development of Deep Vein Thrombosis.
- During sustained periods of immobility, like flying, the combined effects of venous pooling, reduced flow create the conditions necessary for thrombus activation
- The cost of thrombosis to the NHS is estimated at over £200 million a year.
- Globally this is a cost to health service providers of more than £22 billion each year
- More than 60% of all cases of VTE are associated with hospitalisation, with many events occurring up to 90 days after admission
- VTE aﬀects approximately one in 1000 of the UK population and is a signiﬁcant cause of mortality, long-term disability and chronic ill-health problems
- In Europe, there are 544,000 VTE-related deaths every year
- In the U.S. and Europe, VTE-related events kill more people than AIDS, breast cancer, prostate cancer and motor vehicle crashes combined
- In the UK, up to 60% of VTE cases occur during or after hospitalisation, making it the leading preventable cause of hospital death
- Hospital-acquired blood clots cause an estimated 25,000 preventable deaths each year
Risk Factors for DVT
Older Age Immobility Obesity
History Pregnancy HRT
Surgery Hospitalisation Oral Contraceptives
Long-Haul Travel Cancer Trauma